Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?

IMCR Delivers Growth but Misses Revenue Views

Immunocore reported first-quarter 2026 revenues of $106.7 million, up 14% year over year. Revenues still missed the Zacks Consensus Estimate of $109 million, making the quarter less clean than the sales growth rate suggests.

Earnings told a better story. The company posted earnings of 25 cents per share, compared with the consensus estimate of a loss of 26 cents and earnings of 10 cents per share in the year-ago quarter. That combination points to improving execution, even though top-line expectations were not fully met.

Immunocore Retains a Strong Cash Position

Immunocore ended March 31, 2026, with $844.9 million in cash, cash equivalents and marketable securities, down modestly from $864.2 million at Dec. 31, 2025. That liquidity matters because the company is funding multiple late-stage and earlier-stage programs.

Research and development expenses rose 8.1% year over year to $61.1 million in the first quarter, mainly due to higher clinical development costs. The spending burden is real, but the cash position gives Immunocore room to advance Kimmtrak label-expansion studies and its broader ImmTAC pipeline.

IMCR Trades Above Its Industry Sales Multiple

IMCR trades at 3.4X forward 12-month sales, above 1.9X for the Zacks sub-industry and 2.2X for the broader sector. That premium requires investors to assume continued Kimmtrak execution and meaningful pipeline progress.

The premium looks less demanding against IMCR’s own history. Over the past five years, the stock has traded between 2.8X and 49.8X, with a median of 9.8X. A $37 price target based on 3.6X forward sales suggests limited room for valuation expansion unless future data strengthen the growth case.

Immunocore's Single-Product Risk Looms Large

Kimmtrak remains Immunocore’s only marketed product and the source of its entire top line. The drug is approved for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma and is approved in 39 countries.

That dependence leaves the stock exposed to slower demand, pricing pressure, competitive threats or disappointing label-expansion results. Immunocore also lacks major collaboration agreements for Kimmtrak and its pipeline candidates, which could make broad development and commercialization more difficult.

Bristol Myers BMY is relevant to this competitive frame because Immunocore is studying brenetafusp in combination with Bristol Myers’ Opdivo in first-line advanced cutaneous melanoma. Merck MRK, with Keytruda, also reflects the importance of checkpoint inhibitors in the broader immuno-oncology market where Immunocore seeks to expand.

IMCR's Neutral View Reflects a Mixed Setup

The bottom line is that IMCR is neither a straightforward bullish story nor an easy stock to dismiss. Kimmtrak is growing, five-year survival data support its position in metastatic uveal melanoma and the pipeline could diversify the business over time.

The counterweight is equally clear. Immunocore’s revenues still depend entirely on one product, and the valuation already sits above its sub-industry and sector sales multiples.

No specific Zacks Rank or Zacks Style Scores are supplied, so a formal rank-and-score assessment cannot be made. In the Zacks framework, the Zacks Rank is driven by earnings estimate revisions, while Style Scores help investors judge value, growth and momentum traits alongside that rank.

That makes a cautious, market-aligned view appropriate. Investors can watch IMCR for Kimmtrak’s continued sales trajectory, second-half 2026 cutaneous melanoma data and progress from brenetafusp, while recognizing that single-product risk remains central to the stock’s profile.

IMCR’s Zacks Rank

Immunocore currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research